In February 2024, we initiated a significant partnership with Hoshi University in Japan, focusing on the research of aloe polysaccharide DM1001 for the treatment of gastric mucosal lesions.
Hoshi University has shown strong interest in the potential of DM1001 for gastric mucosal repair, considering the high incidence of gastric cancer and the prevalence of gastric diseases in Japan. This strategic partnership aims to delve into the therapeutic potential of DM1001 for gastric diseases, particularly gastric cancer. By closely collaborating with Hoshi University, we expect to elucidate the clinical effects and mechanisms of DM1001 and provide new treatment options for patients with gastric diseases in Japan and around the world.
